Objective-The goal of this study was to search for an association between a desintegrin-like and metalloprotease thrombospondin type 1 motif, member 13 (ADAMTS13) levels and the occurrence of preeclampsia, its characteristics (time-onset and severity), and its consequences (occurrence of fetal growth restriction or preterm delivery). Methods and Results-We studied 140 pairs of women in a case-control study with 3 matching criteria: maternal age, gestational age, and ethnic origin. We measured ADAMTS13 activity using a fluorescence resonance energy transfer assay with the fluorescence resonance energy transfer-VWF73 peptide. ELISA was used to assess protein antigen levels: ADAMTS13, von Willebrand Factor (VWF), interleukin-6, C-reactive protein, P-selectin, and thrombospondin- Key Words: hypertension Ⅲ pregnancy Ⅲ ADAMTS13 Ⅲ preeclampsia Ⅲ von Willebrand factor P reeclampsia (PE) is the most frequent medical complication during pregnancy, occurring in Ϸ2% to 7% of pregnancies worldwide. 1,2 It is a major cause of perinatal and maternal mortality and morbidity. PE is characterized clinically by new onset hypertension and proteinuria after 20 weeks of gestation (WG). The pathogenesis of PE involves inadequate cytotrophoblast invasion with subsequent abnormal placentation, resulting in placental hypoperfusion and ischemia with microthrombotic lesions. 3, 4 The ischemic placenta releases various molecules, including cytokines, antiangiogenic peptides, free reactive oxygen species that induce systemic maternal endothelial dysfunction, and excessive general inflammatory responses. 5, 6 The pathophysiology of the placental microthrombosis observed in PE is obviously multifactorial and likely involves both the endothelium and plasma proteins. Among the various plasma proteins involved in thrombosis, the von Willebrand factor (VWF)/a desintegrin-like and metalloprotease thrombospondin type 1 motif, member 13 (ADAMTS13) couple is interesting to focus on, considering this specific hemorheologic context. VWF is a large multimeric plasma glycoprotein that notably mediates platelet adhesion and aggregation at high shear stress conditions thanks to its multimeric structure. 7 It is synthesized in endothelial cells and megakaryocytes and respectively stored in Weibel-Palade bodies and ␣ granules; VWF is formed in these compartments as ultralarge and very active VWF multimers. ADAMTS13 is a zinc metalloprotease that specifically cleaves the bond between amino acids Tyr1605 and Met1606 in the A2 domain of VWF exposed by shear stress. This protease activity reduces VWF molecular weight and consequently also its platelet-tethering function. 7, 8 A severely deficient ADAMTS13 activity (less than 5% of
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Methods

Patients
In this study, 140 case-control matched pairs were randomly chosen among the 184 pairs of the Search for an Association Between CX3CR1 and V2491 Polymorphism, Preeclampsia and Endothelial Injury (ECLAXIR) study. The ECLAXIR study was a multicenter case-control study for which 368 white pregnant women were enrolled between May 2003 and October 2007. 18 The cases were pregnant women with PE, who were enrolled at time of diagnosis. They were matched with normotensive pregnant women (controls) for maternal age (Ϯ2 years), gestational age (Ϯ2 weeks), and ethnic origin (European or Maghrebian). Controls who developed PE after enrollment were excluded.
Written informed consent was obtained from each woman before enrollment and blood sampling. The ECLAXIR study was approved by the ethics committee (Comité de Protection des Personnes dans la Recherche Biomédicale) of Hôpital Bichat-Claude Bernard (Paris, France). Further use of the samples in the ADAMSIE study was approved by the ethics committee (Comité de Protection des Personnes, Ile-de-France IX) of Hôpital Henri Mondor (Créteil, France).
PE was defined according to the American Congress of Obstetricians and Gynecologists 19 as elevated blood pressure (Ն140/ 90 mm Hg) occurring after 20 WG with previously normal blood pressure, and proteinuria (Ն0.3 g in a 24-hour urine specimen).
Severe PE was defined by the American Congress of Obstetricians and Gynecologists 19 as the presence of at least 2 of the following criteria: blood pressure Ն160/110 mm Hg in 2 measurements 4 hours apart while the patient is on bed rest; proteinuria Ն5 g in a 24-hour urine specimen; oliguria of less than 25 mL per hour; cerebral or visual disturbances; pulmonary edema or cyanosis; epigastric pain; impaired liver function defined as serum aspartate aminotransferase concentrations Ն70 IU/L; thrombocytopenia defined as platelet count lower than 100 Giga/L; fetal growth restriction defined as a z-score lower than Ϫ1.88. This value, calculated according to Salomon et al, 20 is equivalent to a birth weight below the third percentile for gestational age.
PE was defined as early if gestational age at diagnosis was Ͻ34 weeks.
Blood Sampling
Venous blood was collected from all subjects at the time of enrollment (time of PE diagnosis for cases and matched gestational age for controls), before any treatment, into a 1:10 final volume of 3.8% sodium citrate. Platelet-poor plasma was obtained by centrifugation at 2500 g for 20 minutes, and samples were stored at Ϫ80°C until testing.
Laboratory Assays
ADAMTS13 activity was measured using the method of Kokame et al 21 using commercial recombinant fluorescence resonance energy transfer-VWF73 peptide (Peptide Institute Inc, Osaka, Japan) according to the manufacturer's instructions.
ELISA methods were used to assess protein Ag levels: ADAMTS13 (Immubind ADAMTS13 ELISA, American Diagnostica Inc, Stamford, CO), VWF (Asserachrom vWF:Ag, STAGO, Asnières-sur-Seine, France), soluble P-sel (Human sP-Selectin CD62P immunoassay, R&D Systems, Minneapolis, MN), TSP-1 (Human Thrombospondin-1 Quantikine ELISA kit, R&D Systems), and IL-6 (Human IL-6 Quantikine HS, R&D Systems). CRP levels were determined by immunonephelemetry using a high-sensitivity method with the Cardiophase hsCRP kit from Dade Behring Inc (Deerfield, IL). Specific activity of ADAMTS13 was calculated with the ratio of ADAMTS13 activity/Ag.
Statistics
Categorical variables were described using frequency and percentage; continuous variables were described using quartiles. Correlation studies were carried out using the Spearman rank test. Quantitative values were compared between cases and controls using the signed rank test. As the laboratory data were not normally distributed (except for VWF), ADAMTS13 activity and Ag and VWF Ag levels were divided in tertiles based on the distribution of the control group. The measure of association between ADAMTS13 and VWF levels and the occurrence of PE was assessed using conditional logistic regression models, whereas the measure of association with timeonset and severity of PE or occurrence of fetal growth restriction or preterm delivery was assessed using unconditional logistic regression. Multivariate analysis was performed according to forward stepwise model selection procedure. The odds ratios (OR) and their 95% CIs were calculated using the lowest tertile of the control group as the reference for VWF Ag and the highest tertile of this group as the reference for ADAMTS13 levels. Adjustments were done for VWF Ag or ADAMTS13 levels and further for PE risk factors (pregestational body mass index Ͼ30 kg/m 2 , nulliparity, multiple pregnancy, personal history of thrombosis, connective tissue disease, or antiphospholipid antibody syndrome). The relationship between the studied variables and PE characteristics (time-onset and severity) or complications (occurrence of fetal growth restriction Ͻ10 th percentile (z-scoreϭϪ1.28) and preterm delivery before 37 WG) were determined using unconditional logistic regression analysis after dividing the levels into tertiles based on their distribution in the case group. All analyses were performed using SAS version 9.1 (SAS Institute, Inc, Cary, NC). Table 1 shows general demographic, obstetric, and medical characteristics of the study population. Patients and controls were matched on 3 criteria: maternal age (Ϯ2 years) (mean, 31 years), gestational age at enrollment (Ϯ2 weeks) (mean, 34 weeks), and ethnic origin (113 pairs were from Europe, 25 pairs were from the Maghreb, and 2 pairs had mixed European/Maghrebian origins). The number of patients and controls with O blood group were similar in the 2 groups. As expected, PE risk factors were more frequent in cases than in controls: obesity (defined as pregestational body mass index Ͼ30 kg/m 2 ) (PϽ0.01), nulliparity (77.9% versus 55.7%), multiple pregnancy (7.1% versus 1.4%), and personal (6.5% versus 0%) and familial (10.8% versus 1.4%) history of PE. Cases were also more likely than controls to have a preterm delivery (69.8% versus 4.3%) or a fetal growth restriction (13.0% versus 2.2%).
Results
Study Population
Among cases, 45.7% had early-onset PE, and 47.1% had severe PE.
Laboratory Assays
The results of plasma levels of ADAMTS13 (activity, specific activity, and Ag), VWF:Ag, IL-6, CRP, P-sel, and TSP-1 measured in 140 cases and 140 controls are shown in Table 2 . All markers displayed significantly different means between cases and controls except for TSP-1 and ADAMTS13 specific activity (activity/Ag ratio). We found weak correlations between ADAMTS13 activity or Ag levels and VWF:Ag (Figure) . Weak correlations were also found between ADAMTS13 activity or Ag levels and either IL-6 (rϭϪ0. 17 In contrast, we found no significant correlation between P-sel or TSP-1 levels and ADAMTS13 (activity or Ag) (all probability values Ն0.1).
VWF Ag levels were dependent on blood group: mean value 277Ϯ137 IU/mL in subjects with O blood group versus 300Ϯ130 IU/mL otherwise. No relationship was found between blood group and ADAMTS13 levels: 71Ϯ16 (O blood group) versus 72Ϯ18% (non-O blood group). We also made further adjustments for O blood group, P-sel, and TSP-1 levels (OR3) or IL-6 and CRP levels (OR4) in a subgroup (nϭ109) because of missing data, with similar demographic characteristics (data not shown). The association of the lowest levels of ADAMTS13 with PE is also independent of O blood group, TSP-1, and P-sel (OR3 of 16 Our results also show a significant association between VWF:Ag highest levels (Ͼ242 IU/mL) and PE, independent of ADAMTS13 activity and PE risk factors (OR2 of 55 ), IL-6, CRP, TSP-1, or P-sel levels (Table 3) .
ADAMTS13 and PE
PE Characteristics and Complications
We then searched for an association between ADAMTS13 concentration and either the time-onset or the severity of PE (Table 4) . Our results show that the lowest levels of ADAMTS13 activity (Յ57%) were significantly associated with early-onset PE with an OR of 2.5 (1.1 to 5.8). Severe PE was associated with the highest levels of P-sel (Ͼ57 ng/mL) with an OR of 3.4 (1.2 to 9.7).
We also searched for an association with the occurrence of a fetal growth restriction or a preterm delivery. Our results show no association between ADAMTS13 (activity or Ag), VWF:Ag, P-sel, or TSP-1 levels and any of these complications (data not shown).
Discussion
In this case-control study including 140 pairs of pregnant women, we showed for the first time an independent association between ADAMTS13 plasma levels and PE. Decreased levels of ADAMTS13 activity (Յ70%) or Ag (Յ592 ng/mL) were significantly associated with PE after adjustment for VWF:Ag levels and for PE risk factors. By contrast, the activity/Ag ratio did not differ significantly between the 2 groups, thus indicating the quantitative nature of the defect. Our results are at variance with the study by Molvarec et al, 22 who did not find any association between ADAMTS13 and PE. Several points may explain this discrepancy: first, the larger number of patients of our study (140 versus 67); second, the strict matching criteria between cases and controls in the current study; and third, an earlier gestational age at enrollment in our study (34 versus 38 weeks) . Interestingly, decreased ADAMTS13 activity levels have been reported in hemolysis, elevated liver enzymes, and low platelet count syndrome, a severe complication of PE. 23 In this specific study on hemolysis, elevated liver enzymes, and low platelet count syndrome, 23 increased amounts of active VWF related to acute endothelial cell activation and decreased ADAMTS13 activity could be observed. Also, in agreement with our results, several other studies reported increased levels of VWF as a marker of endothelial dysfunction in PE. 18 Severe ADAMTS13 deficiency is associated with thrombocytopenic purpura, and its involvement in the pathogenesis of this thrombotic microangiopathy has been clearly established. 26 Besides this extreme case, partial deficiencies of ADAMTS13 have been observed in other contexts. However, the clinical relevance of these partial deficiencies of ADAMTS13 has not been clearly elucidated in these various contexts so far. In physiological conditions, ADAMTS13 is dependent on age: it is decreased in neonates and in individuals Ͼ65 years old. 27, 28 During normal pregnancy, ADAMTS13 mean levels decrease progressively to 23% at the third trimester. 28 More precisely, ADAMTS13 activity begins to decrease at 12 to 16 WG, 29 suggesting an increased sensitivity to thrombotic microangiopathy from the second trimester of pregnancy. In pathology, partial deficiencies of ADAMTS13 have been observed in diseases sharing inflammatory state, including cardiovascular diseases (coronary heart disease, ischemic stroke, peripheral arterial disease), 30 severe sepsis and septic shock, 31,32 myocardial infarction, 30, [33] [34] [35] severe Plasmodium falciparum malaria, 36 alcoholic hepatitis, 37 and antiphospholipid syndrome. 38 In these studies, correlation between ADAMTS13 and VWF levels are pronounced, 32,37 weak, 39 or more usually absent, 31, 33, 38, 40 especially when there is an adjustment for age. 22, 34 In our study, this correlation was weak (rϭϪ0.17 and Ϫ0.14, for ADAMTS13 activity and Ag, respectively), suggesting that the consumption of ADAMTS13 by its increased substrate VWF may only partially explain ADAMTS13 decrease in PE. Recent findings linking ADAMTS13 to inflammation suggest the involvement of other mechanisms to explain ADAMTS13 partial deficiencies. Inflammatory cytokines, including tumor necrosis factor-␣, IL-6, or IL-8, which are increased in PE, 41, 42 have been shown to inhibit ADAMTS13 synthesis or activity in endothelial cells. 14, 15 In the present study, we confirmed a 4-fold IL-6 increase in cases versus controls; this was associated with an increase in CRP level concentration. Although an increase in IL-6 and CRP had no impact on the association of PE with ADAMTS13 Ag, the statistical adjustment on these parameters abolished its association with ADAMTS13 activity. This result is in agreement with similar ADAMTS13-specific activity (activity/Ag ratio) that we observed between PE and control groups and suggests a quantitative decrease of the protein in PE. Nevertheless, the decrease of ADAMTS13 activity in PE appears to be at least partially dependent on IL-6 and CRP levels, as suggested by the results of multivariate analysis. Feys et al reported similar results when comparing groups of patients with inflammatory bowel disease displaying high or low CRP levels (10 mg/L threshold): both ADAMTS13 activity (Pϭ0.11) and Ag (Pϭ0.03) were lower in patients with high CRP levels, although only Ag levels reached statistical significance. 28 Alternatively, ADAMTS13 proteolysis by plasmatic proteases such as thrombin 43 or by proteases released by granulocytes 44 may also be involved.
In addition, as PE patients have a significant proteinuria, decreased ADAMTS13 could also have been a consequence of elimination in the urines. To evaluate the possible involvement of this mechanism, we prospectively collected urine from 11 pregnant women displaying proteinuria (including women with PE and miscellaneous other causes of proteinuria) ranging from 0.21 to 1.92 g/L (mean, 0.67Ϯ0.62 g/L). ADAMTS13 Ag was measured in all samples and was undetectable in all cases. Finally, although not measured in our study, similar total protein concentrations in subjects with PE and normal pregnant controls have been reported, 45 which also argues against a role of increased vascular permeability in ADAMTS13 decrease.
We also found a significant association between ADAMTS13 activity levels (Յ57%) and early-onset PE (before 34 WG), whereas severe PE was associated with increased levels of P-sel Ͼ57 ng/mL, probably because of a more pronounced endothelial lesion or platelet activation. 6, 46 This could indicate that ADAMTS13 is decreased early in PE, but this finding does not indicate the severity of the decrease. Interestingly, decreased serum levels of ADAM12, another member of ADAM family, have been reported in PE. 47, 48 In addition, multiple ADAMTS subtypes have been detected, albeit many at low levels, in total RNA lysates prepared from human term placenta or uterine tissues, suggesting that these metalloproteinases may play important roles in implantation and placentation. 49 A spliced form (2.4 kb of mRNA) of ADAMTS13 has also been identified in placenta, but the expression of the protein in the placenta or any specific cell in placenta has not been explored yet. 50 In our study, placentas from patients or controls were not available, and further study could not be performed.
This study is the first to suggest a link between ADAMTS13 deficiency and PE. We observed an association between decreased ADAMTS13 plasma levels and PE. Our results show that this decrease is quantitative, occurs early, and might be at least partially dependent on inflammation. Decreased ADAMTS13 activity is likely to participate in the increase of circulating VWF levels in PE. Both these proteins constitute a particularly interesting couple because hemodynamics of placental microcirculation offer ideal conditions to both activate VWF and make it very sensitive to any ADAMTS13 defect. A prospective study should be conducted, including placenta analysis to confirm our results.
